Purpose - To describe a clinical case of advanced cancer of the inferior lip, first treated with High Dose Rate (HDR) Brachytherapy (BRTX) as a successful alternative to surgery. Method- In December 2011 a 54-year-old female came to the Department of Maxillofacial Surgery for an extended lesion of the inferior lip and cheek mucosa. Was established a treatment planning that did not include the surgical resection and lip reconstruction, as the patient was suffering from severe systemic clinical disorders. The patient was treated with conventional radiotherapy alone which, due to the onset of grade 3 mucositis, was suspended at 40 Gy of dose delivered. Definitive Hight Dose Rate (HBR) Brachytherapy was applied. HBR-BRTX was performed with a dose of 3 Gy per fraction, two fractions per day at intervals of 6 hours between the two fractions for 6 days. The patient received a total dose of 18 Gy with HDR-BRTX, which is equivalent to 29.18 Gy of conventional radiotherapy dose. Results - At three years follow-up, the patient is disease-free (neither recurrence of primary tumor nor appearance of laterocervical lympho-nodes are present). Conclusion - HDR-BRTX offers the possibility to treat patients with advanced lip cancer who cannot undergo surgical and/or CHT treatments.

Advanced squamous cell carcinoma of the lip (T4b): Is HDR-interstitial brachytherapy a successful alternative to the surgical treatment ?

CUTILLI, Tommaso;DI CESARE, Ernesto
2015

Abstract

Purpose - To describe a clinical case of advanced cancer of the inferior lip, first treated with High Dose Rate (HDR) Brachytherapy (BRTX) as a successful alternative to surgery. Method- In December 2011 a 54-year-old female came to the Department of Maxillofacial Surgery for an extended lesion of the inferior lip and cheek mucosa. Was established a treatment planning that did not include the surgical resection and lip reconstruction, as the patient was suffering from severe systemic clinical disorders. The patient was treated with conventional radiotherapy alone which, due to the onset of grade 3 mucositis, was suspended at 40 Gy of dose delivered. Definitive Hight Dose Rate (HBR) Brachytherapy was applied. HBR-BRTX was performed with a dose of 3 Gy per fraction, two fractions per day at intervals of 6 hours between the two fractions for 6 days. The patient received a total dose of 18 Gy with HDR-BRTX, which is equivalent to 29.18 Gy of conventional radiotherapy dose. Results - At three years follow-up, the patient is disease-free (neither recurrence of primary tumor nor appearance of laterocervical lympho-nodes are present). Conclusion - HDR-BRTX offers the possibility to treat patients with advanced lip cancer who cannot undergo surgical and/or CHT treatments.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11697/1889
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact